|
|
Analysis on the influencing factors of pharmaceutical market size based on supply and demand model and fishbone diagram |
CHEN Juan ZHANG Ting LU Yan OUYANG Zhaolian▲ |
Institute of Medical Information & Library, Chinese Academy of Medical Sciences, Beijing 100020, China |
|
|
Abstract This paper displays the calculation method of market size based on supply and demand model, analyzes the characteristics of the supply and demand curve of the pharmaceutical market, and explores the impact of the shift of the supply and demand curve on the pharmaceutical market size. Then, based on the results of above analysis, the literature research method and the fishbone diagram are adopted to determine the factors affecting the market size of pharmaceutical industry. We find that the market size of pharmaceutical industry is mainly influenced by the following four factors: the patient population, the payment capacity, the policies and the selection range of products. These four factors are further affected by seven secondary factors: population structure, disease spectrum, economic level/income, medical insurance, medical system, industry policy, medical science and technology progress.
|
|
|
|
|
[1] 国务院关于加快培育和发展战略性新兴产业的决定(全文)[J].中国科技产业,2010(10):14-19.
[2] 李树祥,褚淑贞.我国医药产业区域发展对比分析——基于SCP框架以江苏、山东、广东为例[J].现代商贸工业,2017(9):1-3.
[3] 申桂英.国务院发布关于促进医药产业健康发展指导意见[J].精细与专用化学品,2016,24(3):40.
[4] 曼昆.经济学原理[M].北京:机械工业出版社,2003.
[5] 赵忠.健康卫生需求的理论和经验分析方法[J].世界经济,2005(4):33-38.
[6] Suen W,Mo PH. Simple analytics of productive consumption [J]. J Polit Econ,1994,2(102):372-383.
[7] Leibowitz A,Manning WG,Newhouse JP. The demand for prescription drugs as a function of cost-sharing [J]. Soc Sci Med,1985,10(21):1063-1069.
[8] 中国卫生费用核算小组.中国卫生总费用历史回顾和发展预测[J].卫生软科学,2000,14(5):202-213.
[9] Anderson GF,Hussey PS. Population aging:a comparison among industrialized countries [J]. Health Aff,2000,19(3):191-203.
[10] 乡志忠.广东省城镇居民医疗支出的研究[D].广州:暨南大学,2010.
[11] 李丽清,杜福贻,刘巧艳,等.我国人口城镇化对卫生费用的影响[J].中国卫生经济,2016,35(4):51-53.
[12] Yang G,Wang Y,Zeng Y,et al. Rapid health transition in China,1990-2010:findings from the Global Burden of Disease Study 2010 [J]. Lancet,2013,381(9882):1987-2015.
[13] Keynes JM. The general theory of employment,interest,and money [M]. New York:Harcourt,Brace and Company,1936.
[14] 陈洪海,黄丞,陈忠.我国卫生费用与经济增长关系研究[J].预测,2005,24(6):24-27.
[15] Gerdtham U,J?觟nsson B. Price and quantity in international comparisons of health care expenditure [J]. Appl Econ,1991,23(9):1519-1528.
[16] Vogel RJ. Pharmaceutical pricing,price controls,and their effects on pharmaceutical sales and research and development expenditures in the European Union [J]. Clin Ther,2004,26(8):1327-1340.
[17] Manning WG,Newhouse JP,Duan N,et al. Health insurance and the demand for medical care:evidence from a randomized experiment [J]. Am Econ Rev,1987,77(3):251-277.
[18] Cheng SH,Chiang TL. The effect of universal health insurance on health care utilization in Taiwan. Results from a natural experiment [J]. JAMA,1997,278(2):89-93.
[19] 黄枫,甘犁.医疗保险中的道德风险研究——基于微观数据的分析[J].金融研究,2012(5):193-206.
[20] 李茹,郑小华.城镇职工医疗保险对医疗卫生服务的利用及费用影响[J].中国卫生事业管理,2006(8):473-475.
[21] 冯娟,沈晓,向清.浅析医疗保险三方间的委托代理关系[J].中国卫生事业管理,2009(3):171-173.
[22] 陈鸣声.基层医疗机构合理用药激励性规制研究[D].上海:复旦大学,2013.
[23] 国家中长期科学和技术发展规划纲要(2006-2020年)人口与健康部分[J].亚太传统医药,2006,2(7):10.
[24] 我国国民经济和社会发展十二五规划纲要(摘要)[J].农业工程,2011,1(1):133-135.
[25] 《国家“十二五”科学和技术发展规划》关注医药产业[J].中国高新技术企业,2011(10):11.
[26] 张忠伟.《抗菌药物临床应用管理办法》实施前后的用药分析[J].北方药学,2013,10(11):122-123.
[27] 王文清.中国医疗费用快速上涨问题研究[D].北京:中央民族大学,2006. |
|
|
|